Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs

Author:

Levaggi Laura1ORCID,Levaggi Rosella2ORCID

Affiliation:

1. Faculty of Engineering, Free University of Bolzano-Bozen, Piazza Università, 1, 39100 Bolzano, Italy

2. Department of Economics and Management, University of Brescia, Via San Faustino 74b, 25100 Brescia, Italy

Abstract

The high level of regulation of innovative drugs on the market, which is necessary to protect consumers, produces important effects on drug availability and innovation. In public healthcare systems, the need to curb prices comes from expenditure considerations. The aim of price regulation is to obtain a more equitable allocation of the value of an innovative drug between industries and patients (by reducing prices to make drugs more affordable), but it may also reduce access. (In the listing process, the industry may find it more convenient to limit commercialisation to profitable subgroups of patients.) Furthermore, with the advent of personalised medicine, there is another important dimension that has to be considered, namely, incentives to invest in drug personalisation. In this paper, we review and discuss the impact of different pricing rules on the expenditure and availability of new drugs.

Publisher

MDPI AG

Reference108 articles.

1. Frech, H., Pauly, M., Comanor, W., and Martinez, J. (2023). Pharmaceutical Pricing and R&D as a Global Public Good, NBER. Technical Report.

2. Mulcahy, A.W., Schwam, D., and Lovejoy, S.L. (2024). International Prescription Drug Price Comparisons: Estimates Using 2022 Data, RAND Corporation.

3. A holistic view of innovation incentives and pharmaceutical policy reform;Sachs;Health Aff. Sch.,2023

4. Carone, G., Schwierz, C., and Xavier, A. (2012). Cost-Containment Policies in Public Pharmaceutical Spending in the EU, European Commission-Economic and Financial Affairs. European Economy-Economic Papers.

5. Panos, K., Taylor, D., Manning, J., and Carr, M. (2010). Implementing Value-Based Pricing for Pharmaceuticals in the UK, 2020Health.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3